Your browser doesn't support javascript.
loading
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer.
Xuan, Jiachen; Pearson, Richard B; Sanij, Elaine.
Affiliation
  • Xuan J; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Pearson RB; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
  • Sanij E; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
Mol Cell Oncol ; 7(6): 1805256, 2020 Aug 31.
Article in En | MEDLINE | ID: mdl-33235908
ABSTRACT
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Cell Oncol Year: 2020 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Cell Oncol Year: 2020 Document type: Article Affiliation country: Australia